Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 54.80
+2.30 (4.38%)
Aug 14, 2025, 1:30 PM CST
Tanvex BioPharma Company Description
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States.
It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis.
The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial.
The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Tanvex BioPharma, Inc.
| Country | Cayman Islands |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 198 |
| CEO | Stephen Lam |
Contact Details
Address: 802 West Bay Road George Town, KY1-1205 Cayman Islands | |
| Website | tanvex.com |
Stock Details
| Ticker Symbol | 6541 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | KYG8676P1037 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Stephen Lam | Chief Executive Officer and Director |
| Dr. Allen Y. Chao Ph.D. | Founder and Honorary Chairman |
| Angela Luan | Chief Financial Officer and Corporate Governance Officer |
| Val Chen | Vice President of Finance, Director of Operations. Management and Corporate Governance Officer |
| James Williamson | Accounting Officer |
| Zheng Xia | Chief Technology Officer |
| Linda Grillo | Director of Sales and Marketing |
| Marc Goemans | Chief Commercial Officer |
| May Hung | Chief Internal Auditor |
| Hsun-Chiang Hsieh | Secretary |